DYNC1H1 and structural epilepsy: Growing evidence supports the favorable efficacy and safety of KD in patients with epilepsy and MCD.[17,18] Previous studies suggest that KD exerts anti-seizure effects in structural epilepsy, potentially through anti-inflammatory mechanisms.[17] However, further research is needed to elucidate the underlying mechanisms of KD’s anti-seizure effects in DYNC1H1-related epilepsy.